（文章来源：每日经济新闻） 2024年1至12月份，西点药业的营业收入构成为：医药占比99.55%，其他业务占比0.45%。 西点药业（SZ 301130，收盘价：34.1元）8月14日晚间发布公告称，公司第八届第十二次董事会会议于 2025年8月14日在吉林省长春市卫星路1471号公司会议室召开。会议审议了《关于公司全文及其摘要的 议案》等文件。 ...

Group 1 - The core viewpoint of the article is that West Point Pharmaceutical reported its semi-annual performance, showing a slight decline in revenue but an increase in net profit and earnings per share [2] Group 2 - For the first half of 2025, the company's operating revenue was approximately 128 million yuan, a year-on-year decrease of 0.51% [2] - The net profit attributable to shareholders of the listed company was approximately 24.94 million yuan, reflecting a year-on-year increase of 2.02% [2] - The basic earnings per share were 0.3261 yuan, which represents a year-on-year increase of 7.77% [2]

Fundraising Overview - The company raised a total of RMB 455.5322 million through its initial public offering, with a net amount of RMB 390.9331 million after deducting various issuance costs [1][2] - The funds were raised by issuing 20.200986 million shares at a price of RMB 22.55 per share [1] Fund Utilization and Balance - As of December 31, 2022, the company had a remaining balance of RMB 336.43 million in its fundraising account, with RMB 4.70846 million used for projects and RMB 1.69811 million for issuance costs [2] - By December 31, 2023, the remaining balance was RMB 236.3034 million, with RMB 9.35421 million utilized for projects [2] - As of December 31, 2024, the remaining balance was RMB 137.4138 million, with RMB 8.77753 million used for projects [2] - As of June 30, 2025, the remaining balance was RMB 114.5452 million, with RMB 2.37295 million utilized for projects [2] Fund Management - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights [3] - Funds are stored in designated bank accounts, and a tripartite supervision agreement has been signed with the underwriter and banks [3] Project Completion and Remaining Payments - Several projects funded by the raised capital, including the R&D center and marketing network construction, have been completed, with remaining payments totaling RMB 30.1286 million [2][3] - The company has used part of the raised funds to replace self-raised funds for issuance costs, amounting to RMB 4.6433 million [6][11] Idle Fund Management - The company has approved the use of idle funds for cash management, with a limit of RMB 100 million [5][6] - As of June 30, 2025, RMB 42 million of idle funds were allocated for cash management [12]

证券代码：301130 证券简称：西点药业 公告编号：2025-056 吉林省西点药业科技发展股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 8 月 度的议案》。本次关于部分制度的修订事项尚需提交股东大会审议。现将有关情 况公告如下： 为进一步促进公司规范运作，建立健全内部管理机制，根据《中华人民共和 国公司法》 《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》 《深 《关联交易管理制度》 《回购股份 管理制度》 《累积投票制实施细则》 《募集资金管理制度》 《内部审计制度》 《内幕 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上 市公司章程指引》《上市公司股东会规则》等法律、法规及规范性文件的最新规 定，结合公司实际情况，现对公司《独立董事工作制度》《独立董事专门会议规 则》 《对外担保管理制度》 《对外投资管理制度》 特此公告。 吉林省西点药业科技发展股份有限公司董事会 信息知情人登记管理制度》《投资者关系管理制度》《委托理财管理 ...

Group 1 - The company is Jilin Xidian Pharmaceutical Technology Development Co., Ltd. [1] - The document includes financial data for the year 2025, specifically for the first half of the year [2] - The financial data includes details on fund occupation and related party transactions [2] Group 2 - The document outlines non-operating fund occupation and the reasons for such occupations [2] - It specifies the amounts involved in fund occupation and the interest associated with these transactions [2] - The document also mentions the relationships with controlling shareholders and affiliated companies [2]

Core Points - The company establishes rules for independent director meetings to ensure compliance and protect the rights of all shareholders, especially minority shareholders [1] - Independent directors are required to hold at least one regular meeting annually and can convene additional meetings as necessary [2][3] - The company must provide support for the convening of independent director meetings and ensure timely delivery of relevant materials to all independent directors [2][3] Group 1 - Independent director meetings are to be held when specific matters arise, including related party transactions and changes in commitments [1][2] - Meetings can be conducted in person or through other means such as video or phone, ensuring effective communication among independent directors [2][3] - Decisions made during independent director meetings require a majority vote from all independent directors present [3][4] Group 2 - Independent directors must personally attend meetings or provide written opinions if unable to attend [3][4] - Independent directors are obligated to maintain confidentiality regarding meeting discussions and decisions [4][5] - The rules will be executed upon approval by the company's board of directors and will be revised as necessary to comply with national laws and regulations [5]

吉林省西点药业科技发展股份有限公司 第一章 总则 第一条 为了促进吉林省西点药业科技发展股份有限公司（以下简称公司） 的规范运作，维护公司整体利益，保障全体股东特别是中小股东的合法权益不受 损害，根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》），中国证券监督管理委员会（以下简称"中国证 监会"）《上市公司独立董事管理办法》（以下简称《管理办法》）《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《规 范运作指引》）等法律、行政法规、规范性文件和《吉林省西点药业科技发展股 份有限公司章程》（以下简称《公司章程》）的有关规定，制定本制度。 第二章 一般规定 （一）具备注册会计师资格； （二）具有会计、审计或者财务管理专业的高级职称、副教授或以上职称、 博士学位； （三）具有经济管理方面高级职称，且在会计、审计或者财务管理等专业岗 位有五年以上全职工作经验。 第六条 独立董事出现不符合独立性条件或其他不适宜履行独立职责的情形， 由此造成本公司独立董事不符合本制度要求的人数时，公司应按规定补足独立董 事人数。 第七条 独立董事应当持 ...

吉林省西点药业科技发展股份有限公司 第一章 总 则 第一条 为规范和完善吉林省西点药业科技发展股份有限公司（以下简称公 司）募集资金存储、使用、变更、监督和责任追究的制度，明确募集资金使用的 分级审批权限、决策程序、风险控制措施及信息披露要求，保证募集资金项目的 正常进行和有效管理，提高募集资金使用效率，保护股东权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上市公司募集资金监管规则》等法律法规、规范性文件及《吉林省西点药业科 技发展股份有限公司章程》（以下简称《公司章程》）规定，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括上市公司实施股权激励 计划募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能 ...

Core Points - The document outlines the procedures and principles for the resignation of directors at Jilin Xidian Pharmaceutical Technology Development Co., Ltd, ensuring compliance with laws and regulations [1][2][3] - The company emphasizes the importance of maintaining governance stability and protecting shareholder rights during the director resignation process [1][2] Group 1: Resignation Procedures - Directors who fail to attend board meetings twice consecutively without delegation are considered unable to fulfill their duties, leading to a recommendation for their replacement [2] - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company [2] - The company must disclose the resignation details within two trading days and complete the re-election of directors within sixty days to ensure compliance with legal requirements [2][3] Group 2: Responsibilities and Obligations of Resigning Directors - Resigning directors must complete all handover procedures within five days of their official departure, including the transfer of relevant documents and responsibilities [4] - Directors are required to continue fulfilling any public commitments made during their tenure, even after resignation [4][5] - The confidentiality obligations regarding company trade secrets remain in effect after a director's departure until such information becomes public [5] Group 3: Shareholding Management - Resigning directors are prohibited from transferring their shares within six months of leaving the company [6] - Any changes in shareholding must comply with previously made commitments regarding shareholding proportions and durations [6][6] - The company secretary is responsible for monitoring the shareholding changes of resigning directors and reporting to regulatory authorities if necessary [6]

吉林省西点药业科技发展股份有限公司 第一章 总则 第一条 为规范吉林省西点药业科技发展股份有限公司（以下简称"本公司" 或"公司"）重大信息内部报告工作，保证公司内部重大信息的快速传递、归集 和有效管理，及时、准确、全面、完整地披露信息，维护投资者的合法权益，根 据《中华人民共和国公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"） 《上市公司信息披露管理办法》《深圳证券交易所创业板股票上市规则》（以下 简称"《上市规则》"）《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律法规及《吉林省西点药业科技发展股份有 限公司章程》（以下简称"《公司章程》"）的要求，结合公司实际，制定本制 度。 第二条 公司重大信息报告制度是指当出现、发生或即将发生可能对公司股 票及其衍生品种交易价格或者投资决策产生较大影响的情形或事项（以下简称重 大信息、重大事件或者重大事项）时，按照本制度规定负有报告义务的有关人员 和公司，应当在第一时间将相关信息向公司董事会和董事会秘书报告的制度。 第三条 董事会秘书负责组织实施具体的信息披露工作。证券部为公司信息 披露工作的管理部门，负责公开信息 ...